Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 3 Other hematologic neoplasm 2 Lymphoid 2 Dermatologic 2 Thoracic 1 Sarcoma 1 Plasma cell 1 Myeloid 1 Gastrointestinal 1

Conditions

Lung Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 510 Cisplatin 410 Pemetrexed 400 Radiotherapy 285 Docetaxel 244 Paclitaxel 227 pembrolizumab 226 Gemcitabine 198 Drug Therapy 191 Bevacizumab 190 Erlotinib Hydrochloride 189 Radiosurgery 177 Nivolumab 168 Etoposide 155 durvalumab 154 osimertinib 126 atezolizumab 109 Gefitinib 96 Blood Specimen Collection 93 Magnetic Resonance Spectroscopy 91 Vinorelbine 90 anlotinib 88 Surgical Procedures, Operative 85 Ipilimumab 62 Immunotherapy 62 Surveys and Questionnaires 60 sintilimab 59 Specimen Handling 59 tislelizumab 58 Irinotecan 57

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × flt3 ligand protein × Thoracic × Clear all

NCT04491084 2024-02-28

FLT3

Albert Einstein College of Medicine

Phase 1/2 Terminated

5 enrolled 8 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡